Concepedia

Mike I. Walton

MI

8

Publications

674

Citations

8

H-Index

2004

Active since

Affiliations

Institute of Cancer Research(Current)

Cancer Research UK

Mike I. Walton is an author at Institute of Cancer Research specializing in radiation oncology, pathology, and tumor biology.

Top concepts

Publications per year

2004–2015

8

Publications

8

The Cyclin-dependent Kinase Inhibitor CYC202 (<b><i>R</i></b>-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway

Steven R. Whittaker, Mike I. Walton, Michelle D. Garrett et al. · Cancer Research · 2004 · 192 citations · Full text

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Mike I. Walton, Paul D. Eve, Angela Hayes et al. · Clinical Cancer Research · 2012 · 92 citations · Full text

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Timothy A. Yap, Mike I. Walton, Kyla M. Grimshaw et al. · Clinical Cancer Research · 2012 · 90 citations · Full text

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter et al. · Molecular Cancer Therapeutics · 2010 · 86 citations · Full text

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

Mike I. Walton, Paul D. Eve, Angela Hayes et al. · Oncotarget · 2015 · 68 citations · Full text

, , +19

Rows per page

1–5 of 8